Deltex Medical Group PLC Excellent Results from New Trial

TIDMDEMG

Deltex Medical Group PLC

09 June 2017

9 June 2017

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

First randomised trial in thoracic surgery published: ODM more than halves complications and reduces length of hospital stay by two days

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the publication of a new trial showing excellent results from using ODM in thoracic surgery.

The results of the randomised controlled trial of 100 patients undergoing lung surgery at the University of Freiburg in Germany have been published online by the British Journal of Anaesthesia. Vascular fluids and vaso-active drugs were administered during surgery in accordance with Enhanced Recovery After Surgery ('ERAS') Society recommended protocols.

Nine fewer ODM patients (six v 15) suffered post-operative pulmonary complications and ODM patients had a two day shorter stay in hospital (nine v 11 days).

This is the first published randomised controlled trial studying ODM use during thoracic surgery.

Reference: Kaufmann et al. Oesophageal Doppler guided goal-directed haemodynamic therapy in thoracic surgery - a single centre randomized parallel-arm trial. BJA: 118 (6): 852-61 (2017).

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is excellent news for large numbers of patients undergoing lung resection with one in five of them avoiding a dangerous, life shortening, complication. The trial allows us to target thoracic surgery on top of those other specific types of surgery where the value of ODM has previously been demonstrated.

"In the NHS in England there are around 40,000 patients a year undergoing higher risk thoracic procedures with a risk of post-operative death within 30 days of 1% or higher and very few of these have fluids or vaso-active drugs administered with the aid of ODM."

For further information, please contact:-

 
 Deltex Medical Group            01243 774 837 
  plc                             [e-mail] 
 Nigel Keen, Chairman 
 Ewan Phillips, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser & 
  Broker 
 Arden Partners plc              020 7614 5900 
 Chris Hardie 
 
   Financial Public Relations 
 IFC Advisory                    0203 053 8671 
 Tim Metcalfe 
  Graham Herring 
  Heather Armstrong 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which sets creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable products.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFPMMTMBJMTMR

(END) Dow Jones Newswires

June 09, 2017 02:00 ET (06:00 GMT)